WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (OTCQB: CVRS), a leading developer of precision vascular robotics, will showcase its CorPath® System at the upcoming American College of Cardiology’s (ACC) 64th Annual Scientific Session & Expo, March 14 – 16 in San Diego, CA.
The CorPath System is the first FDA-cleared medical device to provide robotic-assistance in PCI procedures. It enables physicians to perform procedures while seated in a lead-lined interventional cockpit protected from radiation exposure. The CorPath System's proprietary technology allows cardiologists to advance stents and guidewires millimeter-by-millimeter using digital controls.
“The Interventional Cardiology community has only recently focused on the occupational hazards in the cath lab and on efforts to minimize health risks to physicians,” said Michael Ragosta, M.D., Medical Director for Interventional Cardiology, University of Virginia Health System. “Our facility is utilizing technologies such as the CorPath System to greatly reduce our radiation exposure and reduce our risk of orthopedic injury and disability.”
“Occupational Health Hazards of Working in the Interventional Laboratory,” a study recently published in the Journal of the American College of Cardiology (JACC), found that musculoskeletal pain was more common among healthcare workers participating in interventional procedures. In his editorial comment included in the same issue of JACC, James A. Goldstein, M.D. reiterated that operator safety must be prioritized and innovations, such as robotics, can create healthier workplaces for physicians.
Occupational safety and additional benefits of robotic PCI will also be highlighted in a presentation at ACC.15 provided by Giora Weisz, M.D., Chairman of Cardiology, Shaare Zedek Medical Center, as part of Scientific Session 2634 – Optimizing PCI Care Processes. The CME/CNE accredited session will take place on Monday, March 16, in room 6F.
“There are a growing number of voices pushing for improved standards of safety in interventional cardiology, reinforcing that the issue of cath lab occupational hazards is becoming a priority within hospitals,” said David Handler, President and CEO, Corindus Vascular Robotics. “It is important that our industry aligns in support of those providing care. We believe that hospitals should empower and protect their interventional cardiologists with the safety of new technologies.”
To learn more about the CorPath System, visit booth #1937 at ACC.15. For additional information, visit www.corindus.com.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company’s FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help physicians potentially provide better clinical outcomes and minimize the costs associated with complications through improper stent placement during manual PCI procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations regarding future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus’ financial results is included from time to time in the “Forward Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Corindus’ periodic and current filings with the SEC, as well as those discussed under the “Risk Factors” and “Forward Looking Statements” section of Corindus' Prospectus, dated January 16, 2015, filed with the SEC and available on Corindus’ website at http://www.corindus.com/about-corindus/investor-relations. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.